MOVE Quote, Financials, Valuation and Earnings

Intelligent Bio Solutions, Inc. has a net margin of -5036.25% compared to Movano, Inc.'s net margin of -269.38%. Movano, Inc.'s return on equity of -410.28% beat Intelligent Bio Solutions, Inc.'s return on equity of -255.54%.

Movano, Inc. has a consensus price target of $30.00, signalling upside risk potential of 3905.34%. On the other hand Intelligent Bio Solutions, Inc. has an analysts' consensus of -- which suggests that it could grow by 569.64%. Given that Movano, Inc. has higher upside potential than Intelligent Bio Solutions, Inc., analysts believe Movano, Inc. is more attractive than Intelligent Bio Solutions, Inc..

Movano, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intelligent Bio Solutions, Inc. has a beta of 4.455, suggesting its more volatile than the S&P 500 by 345.491%.

Movano, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Movano, Inc. pays -- of its earnings as a dividend. Intelligent Bio Solutions, Inc. pays out -- of its earnings as a dividend.

Movano, Inc. quarterly revenues are $80K, which are smaller than Intelligent Bio Solutions, Inc. quarterly revenues of $1.1M. Movano, Inc.'s net income of -$4M is lower than Intelligent Bio Solutions, Inc.'s net income of -$3M. Notably, Movano, Inc.'s price-to-earnings ratio is -- while Intelligent Bio Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Movano, Inc. is 11.34x versus 35.62x for Intelligent Bio Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools, Inc. has a net margin of -5036.25% compared to Movano, Inc.'s net margin of -162.05%. Movano, Inc.'s return on equity of -410.28% beat Standard BioTools, Inc.'s return on equity of -24.44%.

Movano, Inc. has a consensus price target of $30.00, signalling upside risk potential of 3905.34%. On the other hand Standard BioTools, Inc. has an analysts' consensus of $1.55 which suggests that it could grow by 0.65%. Given that Movano, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe Movano, Inc. is more attractive than Standard BioTools, Inc..

Movano, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Standard BioTools, Inc. has a beta of 1.264, suggesting its more volatile than the S&P 500 by 26.42%.

Movano, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Movano, Inc. pays -- of its earnings as a dividend. Standard BioTools, Inc. pays out -- of its earnings as a dividend.

Movano, Inc. quarterly revenues are $80K, which are smaller than Standard BioTools, Inc. quarterly revenues of $19.6M. Movano, Inc.'s net income of -$4M is higher than Standard BioTools, Inc.'s net income of -$31.7M. Notably, Movano, Inc.'s price-to-earnings ratio is -- while Standard BioTools, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Movano, Inc. is 11.34x versus 4.53x for Standard BioTools, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR, Inc. has a net margin of -5036.25% compared to Movano, Inc.'s net margin of -25.94%. Movano, Inc.'s return on equity of -410.28% beat LENSAR, Inc.'s return on equity of -1013.45%.

Movano, Inc. has a consensus price target of $30.00, signalling upside risk potential of 3905.34%. On the other hand LENSAR, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 29.65%. Given that Movano, Inc. has higher upside potential than LENSAR, Inc., analysts believe Movano, Inc. is more attractive than LENSAR, Inc..

Movano, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENSAR, Inc. has a beta of 0.695, suggesting its less volatile than the S&P 500 by 30.495%.

Movano, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Movano, Inc. pays -- of its earnings as a dividend. LENSAR, Inc. pays out -- of its earnings as a dividend.

Movano, Inc. quarterly revenues are $80K, which are smaller than LENSAR, Inc. quarterly revenues of $14.3M. Movano, Inc.'s net income of -$4M is lower than LENSAR, Inc.'s net income of -$3.7M. Notably, Movano, Inc.'s price-to-earnings ratio is -- while LENSAR, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Movano, Inc. is 11.34x versus 2.32x for LENSAR, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NeuroPace, Inc. has a net margin of -5036.25% compared to Movano, Inc.'s net margin of -12.78%. Movano, Inc.'s return on equity of -410.28% beat NeuroPace, Inc.'s return on equity of -149.8%.

Movano, Inc. has a consensus price target of $30.00, signalling upside risk potential of 3905.34%. On the other hand NeuroPace, Inc. has an analysts' consensus of $19.25 which suggests that it could grow by 15.06%. Given that Movano, Inc. has higher upside potential than NeuroPace, Inc., analysts believe Movano, Inc. is more attractive than NeuroPace, Inc..

Movano, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NeuroPace, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Movano, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroPace, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Movano, Inc. pays -- of its earnings as a dividend. NeuroPace, Inc. pays out -- of its earnings as a dividend.

Movano, Inc. quarterly revenues are $80K, which are smaller than NeuroPace, Inc. quarterly revenues of $27.4M. Movano, Inc.'s net income of -$4M is lower than NeuroPace, Inc.'s net income of -$3.5M. Notably, Movano, Inc.'s price-to-earnings ratio is -- while NeuroPace, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Movano, Inc. is 11.34x versus 5.62x for NeuroPace, Inc.. Usually stocks with elevated PS ratios are considered overvalued.